XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast
Cancer Treatment Reviews
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Therapeutics Advances in Medical Oncology
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Current Treatment Options in Oncology
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Clinical Advances in Hematology & Oncology
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer
The Lancet
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Nature Reviews. Drug Discovery
Targeting HER2-positive breast cancer: advances and future directions
Journal of Clinical Oncology
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial